Format

Send to

Choose Destination
J Proteomics. 2013 Jun 24;85:44-52. doi: 10.1016/j.jprot.2013.04.029. Epub 2013 Apr 30.

Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast.

Author information

1
Biopolymers and Proteomics Unit, IRCCS AOU San Martino-IST, San Martino University Hospital and National Cancer Research Institute, Genoa, Italy.

Abstract

Gross cystic disease (GCDB) is a breast benign condition predisposing to breast cancer. Cryopreserved sera from GCDB patients, some of whom later developed a cancer (cases), were studied to identify potential risk markers. A MALDI-TOF mass spectrometry analysis found several complement C3f fragments having a significant increased abundance in cases compared to controls. After multivariate analysis, the full-length form of C3f maintained a predictive value of breast cancer risk. Higher levels of C3f in the serum of women affected by a benign condition like GCDB thus appears to be correlated to the development of breast cancer even 20 years later.

BIOLOGICAL SIGNIFICANCE:

Increased complement system activation has been found in the sera of women affected by GCDB who developed a breast cancer, even twenty or more years later. C3f may predict an increased breast cancer risk in the healthy population and in women affected by predisposing conditions.

PMID:
23639844
DOI:
10.1016/j.jprot.2013.04.029
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center